Navigation Links
Prescient Medical, Inc. Achieves Successful Clinical Debut of vProtect(TM) Luminal Shield
Date:5/29/2008

Novel self-expanding intracoronary prosthesis successfully placed in three

patients with coronary artery disease

DOYLESTOWN, Pa., May 29 /PRNewswire/ -- Three patients with established cardiac ischemia recently became the first recipients of the vProtect Luminal Shield, a self-expanding intracoronary prosthesis designed to limit arterial injury that typically occurs when stents are deployed. The Shield also provides robust biocompatible support for the vessel to ensure that the target coronary artery will remain patent after placement.

The patients were treated May 8-9 by Juan F. Granada, MD (Cardiovascular Research Foundation, New York, NY) and Juan A. Delgado, MD (Corbic Institute-MUA) at the Corbic Institute-MUA in Envigado, Colombia. The target lesions ranged from 60% to 80% stenosis before the vProtect Luminal Shields were deployed.

In the first patient, a 75% occlusion in the mid-circumflex coronary artery underwent pre-dilatation at low pressure with a 2.5 x 9 mm balloon and then received a 3.5 x 15 mm luminal shield. After gentle post-dilatation, angiography revealed that blood flow had been restored to the distal portion of the treated vessel.

In the second patient, an 80% occlusion in the middle of the left anterior descending (LAD) branch required pre-dilatation with a 2.5 x 9 mm balloon. Additional lumen gain was achieved by Shield placement and post-dilatation, again achieving restoration of blood flow distal to the treated segment.

The third patient was a challenging case with a 65% occlusion in the mid-LAD, located in a bend near a side branch ostium. The vProtect Luminal Shield was chosen for this patient based on its mechanical properties, including high vascular conformability. Because of its flexibility, the vProtect Luminal Shield was able to access the tortuous anatomy and cross the lesion successfully. Restoration of flow was achieved without angiographic evidence of straightening of the target vessel, a common occurrence with rigid balloon-expandable stents. In addition, the side branch was preserved without evidence of plaque shifting or worsening stenosis.

"The vProtect Luminal Shield and delivery system performed extremely well," according to Dr. Granada. "The three patients we treated presented with lesions representative of what we see in daily clinical practice and we were able to cross these lesions and deliver the device safely in each case. Although the vProtect Luminal Shield has ultra-thin struts to promote healing, it maintains an intrinsic radial force that matches the vessel compliance. I am very pleased with these early results," Dr. Granada said.

For more information about Prescient Medical and its products, contact Ilana Odess at (917) 941-9990.

About Prescient Medical, Inc.

Prescient Medical, Inc. is a privately held medical device company dedicated to reducing deaths from heart attacks, the leading cause of death in much of the world. For more information, please visit our website at http://www.prescientmedical.com or call +1-866-376-0500.


'/>"/>
SOURCE Prescient Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
2. Pharmacopeias First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients
3. CureDMs Diabetes Therapy Achieves Major Development Milestone
4. EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program
5. Bionomics Achieves US$1 Million Milestone Payment from Genmab
6. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
7. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
8. Surface Logix Achieves Objectives With SLx-2101 in Phase 2a Clinical Trial in Hypertension
9. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
10. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
11. Cethromycin Achieves All Endpoints in Second Pivotal Phase III Trial for Treatment of Pneumonia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama Information, ... billion in 2015.  Though these are challenging times ... opportunity for success for companies that remain optimistic ... of new growth prospects medical device companies spend ... and development (R&D) than do companies in other ...
(Date:5/25/2016)... PARIS , May 25, 2016 ... system disorders, announces that an oral presentation entitled "High doses ... the MS-SPI trial" will be given by Professor Ayman ... the 2nd Congress of the European Academy of Neurology (EAN) ... "MS and related disorders 3" will take place on Sunday, ...
Breaking Medicine Technology:
(Date:5/26/2016)... , ... May 26, 2016 , ... ... clinical outcomes, hosted members and suppliers for its inaugural Member Conference at the ... their mission of elevating the operational health of America’s healthcare providers. , The ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through ... a partner for the Tamika Catchings Legacy Tour that will commemorate the ... in hardwood basketball surfaces in all forms and levels of the game, Connor Sports ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
(Date:5/26/2016)... ... ... There are nearly 14.5 million people living with and beyond cancer in the ... 2016, communities around the world will gather to recognize these cancer survivors as part ... is an annual worldwide Celebration of Life that is held on the first Sunday ...
(Date:5/26/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... global clinical supply services, today announced two key appointments and the opening of ... strategic growth plans in the Asia Pacific region. , Howard Kim has joined ...
Breaking Medicine News(10 mins):